Cargando…
Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils
Immunotherapy against alpha-synuclein (α-syn) is a promising novel treatment strategy for Parkinson's disease (PD) and related α-synucleinopathies. We have previously shown that systemic treatment with the monoclonal oligomer/protofibril-selective antibody mAb47 targeting cytotoxic α-syn leads...
Autores principales: | Ekmark-Lewén, S., Aniszewska, A., Molisak, A., Gumucio, A., Lindström, V., Kahle, P.J., Nordström, E., Möller, C., Fälting, J., Lannfelt, L., Bergström, J., Ingelsson, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407822/ https://www.ncbi.nlm.nih.gov/pubmed/37559953 http://dx.doi.org/10.1016/j.nbas.2023.100086 |
Ejemplares similares
-
Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice
por: Roshanbin, Sahar, et al.
Publicado: (2021) -
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice
por: Aniszewska, Agata, et al.
Publicado: (2022) -
Early fine motor impairment and behavioral dysfunction in (Thy‐1)‐h[A30P] alpha‐synuclein mice
por: Ekmark‐Lewén, Sara, et al.
Publicado: (2018) -
Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes
por: Gustafsson, Gabriel, et al.
Publicado: (2017) -
Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
por: Syvänen, Stina, et al.
Publicado: (2018)